Appoints Sanjay Batra, Ph.D., F.A.C.C., as Senior Vice President, Development
MALVERN, Pa., March 1 /PRNewswire/ -- Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing products that speed healing and reduce scarring after surgery or dermatologic procedures, today announced the appointment of Sanjay Batra, Ph.D., F.A.C.C., as Senior Vice President, Development.
has more than 15 years of research and development experience in both the biotechnology and pharmaceutical industries, including nine years at Johnson & Johnson
In his role at Garnet BioTherapeutics, Dr. Batra will oversee all clinical development programs including the upcoming Phase II study of the Company's lead compound GBT009, which is under investigation as a post-surgical wound healing agent.
Gerri has built a first class team here and I look forward to joining forces as we achieve our goal of becoming a leader in the field of regenerative medicine," said Dr. Batra
Prior to his time at J&J, Dr. Batra was in clinical development at Bracco Diagnostics, and in preclinical and clinical development at Alliance Pharmaceuticals.
Dr. Batra obtained his Ph.D. in Medical Physiology from the University of Ottawa, Canada and completed his post-doctoral training in Sapporo, Japan and Bern, Switzerland.
is the recipient of numerous awards and has published over 100 papers and abstracts in the area of cardiovascular medicine and physiology.